Randomized Study of Pergolide in Children With Tourette Syndrome
Status:
Completed
Trial end date:
2002-09-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES:
I. Evaluate the presumed mechanism of action of low dose pergolide to act acutely through the
dopaminergic autoreceptor or postsynaptically at D2 sites in children 7 to 17 with tourette
syndrome (GTS).
II. Compare tolerability and safety of pergolide in these patients to standard neuroleptic
therapy via naturalist assessment after 3-6 months of treatment using matched historical
controls on neuroleptics.
III. Determine efficacy of pergolide for tic control in these patients.